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tional impairment, suppression or deletion of antigen-
speciﬁ c T cells appears to be a key determinant of progres-
sion to chronicity11,18. The importance of the cytokine 
milieu in determining viral clearance has been empha-
sized by recent studies19–21. Cytokines are low-molecular-
weight mediators of cellular communication produced by 
multiple cell types in the liver, with the Kupffer cell criti-
cally important. Proinﬂ ammatory cytokines such as in-
terleukin-1, tumor necrosis factor and interleukin-8 are 
acute-phase cytokines and play a role in the liver injury 
of acute and chronic liver diseases22.
Primary HCV infection is asymptomatic in the major-
ity of cases, with 50–80% of individuals developing chron-
ic infection1,2. The immune response is a key component 
in the activation and maintenance of antiviral immunity, 
through induction of cytokines and initiation of the adap-
tive immune response. Clearance of chronic hepatitis C 
virus (HCV) has been associated with early, multi-specif-
ic and sustained CD4+ and CD8+ responses directed 
against HCV epitopes3–12. The pro-inﬂ ammatory cyto-
kines are involved in viral clearance and in metabolic and 
viral hepatic diseases. Th1 cytokines positively correlate 
with hepatic inﬂ ammation in HCV infection13–17. Func-
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A B S T R A C T
Immunoregulatory cytokines inﬂ uence the persistence of hepatitis C virus chronic infection and the extent of liver dam-
age. Interleukin-1 plays an important role in the inﬂ ammatory process. Some studies have demonstrated that IL-1 produc-
tion was impaired in patients with chronic infections of hepatitis C virus, implying that IL-1 may play a role in viral 
clearance. In this study, along with routine laboratory tests, has been performed the analysis of serum levels of proinﬂ am-
matory cytokine IL-1a in order of better understanding and monitoring of chronic hepatitis C. The aim of study was to 
analyze the usefulness of laboratory tests, which are routinely used in the assessment of liver disease with speciﬁ ed im-
munological parameters, in patients with chronic hepatitis C. Total of 60 subjects were divided into two groups: HCV- PCR 
positive and negative group. The control group of 30 healthy participans was included. Apart from standard laboratory 
tests, the analysis included serum levels of cytokine IL-1 a. IL-1a had the highest mean concentration in group of viral 
hepatitis C, with PCR positive test (5.73 pg / mL), and then in of chronic viral hepatitis C, PCR negative test (5.39 pg / mL). 
ANOVA test proves that IL-1a in the healthy group was different from other groups as follows: in relation to HCV- RNA- 
PCR positive patients statistical signiﬁ cance level was p<0.001 (F=32 755); in relation to HCV- RNA- PCR negative 
was also statistically signiﬁ cant at p <0.001 (F=182 361); Cytokine IL-1 was statistically analyzed separately and com-
pared by group 1 and 2 using Student t-test for independent samples. Statistical signiﬁ cance was observed at p=0.026. 
IL-1 a was positively correlated with the duration of the illness (p<0.01) and with serum ALT activity (p<0.01) and serum 
AST activity (p<0.01). Using multivariate analysis model »Factor Analysis«, was made signiﬁ cant stratiﬁ cation predic-
tive parameters in relation to the cytokine IL-1a, stratiﬁ ed signiﬁ cance is indicated as follows: 1. Age, 2. history of receiv-
ing transfusions, 3. ALT, 4. AST, 5. MELD score (negative), 6. Child-Pugh score (negative). IL-1a was signiﬁ cantly ele-
vated in inﬂ ammatory conditions of pronounced activity (PCR positive hepatitis). IL-1a may have important role as 
marker of both inﬂ ammation and hepatic injury, particularly in the course of hepatitis C. Results suggest that inﬂ amma-
tory and immune parameters, analyzed together can signiﬁ cantly contribute to the understanding and predicting of 
chronic liver damage.
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Interleukin-1 (IL-1) has central role in inﬂ ammatory 
process especially acute inﬂ ammation. It is an indicator 
of the intensity of inﬂ ammation activity23. Some studies 
have demonstrated that IL-1 production was impaired in 
patients with chronic hepatitis C, implying that IL-1 may 
play a role in viral clearance19–23.
The objective of this study was to determine and ana-
lyze serum level of IL-1a in patients with chronic hepatitis 
C in correlation of the presence of viral genetic replication 
and functional liver status.
Patients and Methods
The study was conducted as one year, an open, case 
controlled comparative clinical trial.
Before entering the study, each patient reviewed and 
signed an informed consent. All research described in 
study, involving human subjects and eterial derived from 
human subjects complied with ethnical principles. Stan-
dards of Good Clinical Practice, Good Laboratory Practice 
and The declaration of Helsinki were followed.
The study was conducted at the Department of gastro-
enterology and Hepatology, Clinical Centre University of 
Sarajevo.
Patients
Total of 90 patients of either sex, 18–80 years of age, 
were recruited.
Inclusion criteria were patients with positive serum 
HCV antibodies, polymerase chain reaction test was per-
formed. Previous liver biopsy diagnosis of hepatitis C was 
needed, no more than 6 months before study. Duration of 
illness was measured according to ﬁ rst notiﬁ cation of 
liver damage and Anti HCV positivity. Exclusion criteria 
were: presence of liver disease caused by NAFLD/NASH, 
hereditary condition, cardiac liver cirrhosis, liver dis-
ease occurred during pregnancy, vascular disease of the 
liver, primary biliary cirrhosis, as and subjects with liver 
transplant, acute hepatitis, evidence of acute or chron-
ic inﬂ ammatory syndrome of other known origin, immu-
nodeﬁ ciency states.
Respondents with diagnosis od chronic hepatitis C – 60 
patients were divided in two groups:
1. Chronic hepatitis C, HCV-RNA-PCR positive test, anti 
HCV positive
2. Chronic hepatitis C, HCV-RNA-PCR negative test, anti 
HCV positive.
A control group of 30 healthy subjects was included as 
well as group 3.
Methods
A physical examination was carried out and medical 
history was taken during the pre-study visit. The follow-
ing data were recorded from all patients: age, gender, 
BMI, history of narcotics consumption or transfusion re-
ceiving, history of liver disease – liver biopsy, comorbidity.
Biochemical parameters were recorded: full blood 
count, international normalized ratio (INR), active partial 
thromboplastin time (APTT) and routine liver function 
tests including bilirubin, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), alkaline phos-
phatase and gamma-glutamyl transferase, proteinogram. 
Polymerase chain reaction for detecting viral RNA in se-
rum was used.
Serum levels of cytokine IL-1a where determined and 
measured by quantative Sendwich Enzyme Immunoassay 
technique. Monoclonal antibodies specific for IL-1a 
were coated on mikroparticules, which come into con-
tact with the sample, and is based on the occurrence of a 
speciﬁ c color, measuring the intensity, extent and concen-
tration of cytokine in the sample.
Analysis was made from frozen serum samples that 
were collected in serum separator tube. Values were ex-
pressed as pg/ml.
Functional status of the liver was determined by the 
modiﬁ ed Child Pugh and MELD scores.
Statistical analysis
For the processing of data computer program »Statis-
tica for Windows 5.0« was used. Categorical data were 
expressed as proportions (%), and continuous data as 
means (X) ± standard deviation (SD). Statistical methods 
used in this study where: analysis of variance test (ANO-
VA test), multivariate analysis model »Factor Analysis«, 
and Student’s t-test for independent samples. The level of 
signiﬁ cance was p<0.05.
Results
A total of 90 subjects, divided into two groups of 30 pa-
tients, also with a group of 30 healthy subjects treated for 
comparison. The Table 1 shows the basic demographic 
and anthropological parameters of subjects per group, 
which were not signiﬁ cantly different by group (p>0.05).
TABLE 1
BASIC DEMOGRAPHIC AND ANTHROPOLOGICAL 
PARAMETERS OF SUBJECTS PER GROUP




























p>0.05 p>0.05 p>0.05 p>0.05
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Increased enzyme activity was noted in groups of pa-
tients with liver disease compared to the control group of 
healthy subjects (p<0.01). INR and APTT did not signiﬁ -
cantly differ by groups (Table 2) (p>0.05). The values of 
total protein were not signiﬁ cantly different (Table 3). 
There was no statistically signiﬁ cant differences in the 
analysis of hematological parameters (Table 4).
Figure 1 presents average values of interleukin 1 (IL-
1a) in groups.
ANOVA analysis of variance test proves that IL-1a in 
the healthy group (3) was different from other groups as 
follows: in relation to group 1 statistical signiﬁ cance level 
was p<0.001 (F=32 885); in relation  to group 2 was also sta-
tistically signiﬁ cant at p<0.001 (F=180 361);
IL-1a had the highest mean concentration in group 1 
– viral hepatitis C, with PCR positive test (5.88 pg/
ml), and then in group 2- anti HCV positive, PCR negative 
test (5.37 pg/ml).
Cytokine IL-1a was statistically analyzed separate-
ly and compared by groups using Student t-test for inde-
pendent samples. Statistical signiﬁ cance was observed 
between groups 1 and 2 at p=0.026. IL-1 a was positively 
correlated with the duration of the illness (p<0.01) and 
with serum ALT activity (p<0.01) and serum AST activ-
ity (p<0.01). Using multivariate analysis model »Fac-
tor Analysis«, was made signiﬁ cant stratiﬁ cation predic-
tive parameters in relation to the cytokine IL-1a, 
stratiﬁ ed signiﬁ cance is indicated as follows: 1. Age, 2. 
history of receiving transfusions, 3. ALT, 4. AST, 5.
MELD score (negative), 6. Child-Pugh score (negative).
Discussion
In clinical practice, for determining the degree of func-
tional status of liver Child Turcotte Pugh and MELD scor-
ing systems are used. In this study, along with routine lab-
TABLE 2
AVERAGE ACTIVITY VALUES OF ENZYMES, BILIRUBIN, INR AND APTT IN GROUPS
Group Ala AT IU/mL (SD)
Asp AT IU/mL 
(SD)












1 77.77 (43.83) 66.30 (44.40) 110.40 (91.31) 87.41 (27.41) 1.23 (0.21) 40.70 (4.51) 21.41 (26.66) 10.72 (9.08)
2 79.91 (81.96) 80.80 (73.76) 70.53 (29.33) 88.50 (50.47) 1.23 (0.20) 37.69 (4.35) 25.56 (18.11) 9.61 (8.16)
3 33.63 (7.24) 25.03 (6.28) 38.70 (7.43) 86.83 (21.17) 1.09 (0.14) 38.82 (3.68) 10.75 (4.31) 7.28 (1.27)
p<0.05 p<0.05 p<0.05 p>0.05 p>0.05 p>0.05 p<0.05 p<0.05
TABLE 3
STATISTICAL ANALYSIS OF PROTEIN PARAMETERS IN GROUPS.
Group Tot. proteins (g/L) (SD) Albumin (g/L) (SD) Globulin (g/L) (SD) A/G index (SD) FibrinogeN (g/L) (SD)
1 75.03 (7.66) 36.70 (5.82) 38.33 (4.93) 1.05 (0.32) 2.56 (0.77)
2 76.80 (6.70) 39.23 (5.11) 36.57 (5.55) 1.11 (0.24) 2.99 (0.76)
3 73.47 (5.81) 40.63 (4.26) 32.98 (3.36) 1.25 (0.16) 2.67 (0.78)
p>0.05  p>0.05 p>0.05 p>0.05 p>0.05
TABLE 4
STATISTICAL ANALYSIS OF HEMATOLOGICAL PARAMETERS IN GROUPS.
Group Hb (g/L) (SD) Htc MCV (fL) (SD) Le (x109/L) (SD) Tr (x109/L) (SD)
1 145.10 (15.20) 46.01 (3.89) 95.33 (3.42) 6.14 (1.56) 171.38 (68.50)
2 148.50 (20.56) 42.22 (5.60) 94.87 (8.41) 5.79 (1.81) 168.71 (56.61)
3 143.83 (7.60) 40.33 (3.02) 9423.38 (4.84) 6.57 (1.74) 236.13 (60.70)















Fig. 1. The average values of interleukin 1 a (pg/ml) in groups. 
Group 1 – Anti HCV positive, HCV RNA PCR positive. Group 2 
– Ant HCV negative, HCV RNA PCR negative. Group 3 – Healthy 
subjects. ANOVA p<0.01.
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oratory tests, has been performed the analysis of serum 
levels of proinﬂ ammatory cytokine IL-1a in order of bet-
ter understanding and monitoring of chronic hepatitis C.
Measurements of average values of enzyme activity 
(AST, ALT, gGT and AP) and bilirubin in groups showed 
increased activity of these enzymes in groups of patients 
with chronic hepatitis compared to controls, which as ex-
pected due to chronic liver process. The values of total 
protein and hematological parameters were not signiﬁ -
cantly different by groups. Functional indicators of liver 
damage (Child Pugh and MELD scores) showed a correla-
tion in both groups, but not as good assessment system the 
intensity of inﬂ ammation and involvement of the liver ﬁ -
brosis process. What explains their primary purpose in 
evaluating the terminal stages of liver damage.
Statistical analysis of the cytokines analyzed showed 
very impressive results. An analysis of serum level of In-
terleukin-1a showed a high degree of correlation with ac-
tive replication of genetic material (HCV RNA PCR posi-
tive – group 1), resulting in a high degree of statistical 
signiﬁ cance. The most active inﬂ ammatory process oc-
curred in this group, while in group 2 -HCV RNA PCR 
negative inﬂ ammatory reaction has subsided, and has 
been better controlled, but still present, which is consis-
tent with the results.
The increase of IL-1a divert an inﬂ ammatory reaction 
of the predominantly exudative – cellular responses, un-
der the inﬂ uence of IL-1a, to ﬁ broblast – granulation re-
sponse. Histologically speaking, at this stage to expect 
signiﬁ cant activity of ﬁ broblasts, ﬁ brous components of 
reproduction in inﬂ ammatory region. If this process is 
extremely intense generated signiﬁ cant predisposition to 
replace functional liver tissue with ﬁ brosis, which may 
have long-term pathological changes in liver structure, 
and then the functional repercussions. At this stage it is 
necessary to evaluate how favorable is »repair inﬂ amma-
tory reaction«. If it is too intense, the stabilization of the 
formed ﬁ brous tissue, in the long term, could functionally 
suppress liver tissue. It follows that monitoring the chang-
es in concentrations of IL-1 and other cytokines (TGF-b1) 
might have a use value »predictor of cirrhosis«. Studies 
suggest that elevated levels of IL-1 in samples of liver tis-
sue indicate the pronounced activity of hepatitis C24 and 
it is to expect increased serum levels of this cytokine in 
this conditions, which results from this research.
Recent studies associates levels of cytokines, as im-
mune response parameters, with the expected response to 
antiviral therapy25. IL 1 could here, possibly, ﬁ nd its ap-
plication, which is the subject of further research.
Conclusion
Analysis of serum levels of proinﬂ ammatory cytokine 
IL-1a and functional status of the liver revealed detailed 
information about the chronic hepatitis. IL-1a was sig-
niﬁ cantlly elevated in inﬂ ammatory conditions of pro-
nounced activity (PCR positive hepatitis) and can be used 
as important parameter of inﬂ ammatory activity and ﬁ -
brosis evaluation in chronic liver damage.
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KORISNOST RAZINE SERUMA PREDUPALNOG CITOKINA 1L-1a KOD KRONIČNOG HEPATITISA C
S A Ž E T A K
Imunoregulatorni citokini utječu na prisutnost kronične infekcije virusom hepatitisa C i na opseg oštećenja jetre. 
Interleukin-1 igra važnu ulogu u upalnom procesu. Neke studije su pokazale da je IL-1 produkcija umanjena u paci-
jenata s kroničnom infekcijom s virusom hepatitisa C, što ukazuje da IL-1 ima ulogu u virusnom čišćenju. U ovoj 
studiji, zajedno s rutinskim laboratorijskim testovima, izvršena je analiza serumske razine proupalnih citokina IL-1a 
u cilju boljeg razumijevanja i praćenja kroničnog hepatitisa C. Cilj istraživanja bio je analizirati korisnost laboratorijskih 
testova koji se rutinski koriste u procjeni bolesti jetre s određenim imunološkim parametrima kod bolesnika s kroničnim 
hepatitisom C. Ukupno 60 ispitanika bilo je podijeljeno u dvije skupine: HCV PCR pozitivne i negativne grupe. Kon-
trolna skupina od 30 zdravih učesnika je bila uključena. Osim standardnih laboratorijskih ispitivanja, analizirane su 
serumske razine citokina IL-1 a. IL-1a ima najveću srednju koncentraciju u skupini virusnog hepatitisa C, s PCR pozi-
tivnim testom (5,73 mg/mL), a zatim kod kroničnog virusnog hepatitisa C, s PCR negativnim testom (5,39 mg/mL). 
ANOVA test pokazuje da je IL-1a u zdravoj skupini bio je drugačiji od ostalih skupina kako slijedi: u odnosu na HCV 
RNA PCR pozitivne pacijente statistička granica značajnosti je p<0,001 (F=32 755); u odnosu na HCV RNA PCR nega-
tiv je također statistički značajno uz p<0,001 (F=182 361); citokin IL-1 statistički je analizirano pojedinačno i odnosu 
prema grupi 1 i 2 pomoću studentovog t-testa za nezavisne uzorke. Uočena je statistička značajnost od p=0,026. IL-1a 
pozitivno je povezana s trajanjem bolesti (p<0,01), serumskim ALT (p<0,01) i aktivnosti seruma AST (p<0,01). Korištenjem 
multivarijatne analize modela faktorske analize, stratiﬁ kacijski prediktivni parametar je značajan u odnosu na citokin 
IL-1a, stratiﬁ cirani značaj prikazan na sljedeći način: 1. dob, 2. povijest primanja transfuzije, 3. ALT, 4. AST, 5. MELD 
rezultat (negativan), 6. Child-Pugh rezultat (negativan). IL-1a je značajno povišen u izrazito aktivnim upalnim uvjetima 
(PCR pozitivan hepatitis). IL-1a može imati važnu ulogu kao znak i upale i oštećenja jetre, osobito u tijeku hepatitisa C. 
Rezultati ukazuju na to da analiza upalnih i imunoloških parametara može značajno pridonijeti razumijevanju i 
predviđanju kroničnog oštećenja jetre.
